Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 80Stomach Neoplasms 66Rectal Neoplasms 39Pancreatic Neoplasms 31Colonic Neoplasms 27Esophageal Neoplasms 24Lymphoma, Large B-Cell, Diffuse 20Neoplasms 19Adenocarcinoma 19Cholangiocarcinoma 16Neoplasm Metastasis 15Adenocarcinoma Of Esophagus 14Biliary Tract Neoplasms 12Carcinoma, Non-Small-Cell Lung 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Ovarian Neoplasms 10Gastrointestinal Neoplasms 7Gallbladder Neoplasms 7Carcinoma, Hepatocellular 7Locally Advanced Rectal Cancer 6Esophageal Squamous Cell Carcinoma 6Endometrial Neoplasms 6Recurrence 4Lymphoma 4Carcinoma 4Bile Duct Neoplasms 4Advanced Solid Tumors 4Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Peritoneal Neoplasms 3

Interventions

trastuzumab deruxtecan 2Trastuzumab 2Oxaliplatin 2Fluorouracil 2Cisplatin 2Capecitabine 2pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
HER2-positive Gastric Cancer × Oxaliplatin × 1 year × Clear all
NCT06764875 2026-05-12

A Phase â…¢ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

AstraZeneca

Phase 3 Recruiting
840 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT07332533 2026-01-12

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Shanghai JMT-Bio Inc.

Phase 2/3 Not yet recruiting
490 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡